Meridian Bioscience was founded in 1977 and is headquartered in Cincinnati, US

Meridian Bioscience has an office in Cincinnati

Cincinnati, US (HQ)

3471 River Hills Dr

## Revenue (2016) | $196.1 m |

## Revenue growth (2015-16), % | 1% |

## Gross profit | $127.8 m |

## Gross profit margin (2016), % | 65% |

## Net income (2016) | $32.2 m |

## Market capitalization (21-Mar-2017) | $555 m |

## Closing share price (21-Mar-2017) | $13.3 |

## Cash (30-Sep-2016) | $47.2 m |

Meridian Bioscience's current market capitalization is $555 m.

Meridian Bioscience's revenue was reported to be $196.1 m in 2016 which is a **0.6% increase** from the previous period.

Y, 2013^{} | Y, 2014^{} | Y, 2015^{} | Y, 2016^{} | |
---|---|---|---|---|

## Revenue | $188.7 m | $188.8 m | $194.8 m | $196.1 m |

## Revenue growth, % | 0% | 3% | 1% | |

## Cost of goods sold | $67.6 m | $71.6 m | $72.9 m | $68.3 m |

## Gross profit | $121 m | $117.2 m | $121.9 m | $127.8 m |

## Gross profit Margin, % | 64% | 62% | 63% | 65% |

## Operating expense total | $63.7 m | $64.9 m | $65.8 m | $76.4 m |

## EBIT | $57.3 m | $52.4 m | $56.1 m | $51.4 m |

## EBIT margin, % | 30% | 28% | 29% | 26% |

## Interest expense | $897 k | |||

## Interest income | $44 k | $25 k | $23 k | $67 k |

## Pre tax profit | $57.4 m | $52.1 m | $55.1 m | $50.6 m |

## Income tax expense | $19.3 m | $17.4 m | $19.5 m | $18.4 m |

## Net Income | $38 m | $34.7 m | $35.5 m | $32.2 m |

FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} | |
---|---|---|---|---|

## Cash | $44.3 m | $43 m | $50 m | $47.2 m |

## Accounts Receivable | ||||

## Inventories | $34.8 m | $35.5 m | $35.8 m | $45.1 m |

## Current Assets | $114.1 m | $112.7 m | $122.9 m | $126.8 m |

## Goodwill | $23.1 m | $23.2 m | $22.3 m | $62 m |

## Total Assets | $176.7 m | $176.9 m | $183.3 m | $251.8 m |

## Accounts Payable | $5.6 m | $5 m | $6.6 m | $7.6 m |

## Total Debt | $58.4 m | |||

## Current Liabilities | $21.7 m | $13.7 m | $15.3 m | $22.6 m |

## Non-Current Liabilities | $2.2 m | $2.2 m | $62.8 m | |

## Total Liabilities | $15.9 m | $17.4 m | $85.4 m | |

## Additional Paid-in Capital | $107.4 m | $111.9 m | $117.2 m | $122.4 m |

## Retained Earnings | $46.9 m | $48.9 m | $51.1 m | $49.6 m |

## Total Equity | $155 m | $161 m | $165.9 m | $166.5 m |

## Debt to Equity Ratio | 0.4 x | |||

## Debt to Assets Ratio | 0.2 x | |||

## Financial Leverage | 1.1 x | 1.1 x | 1.1 x | 1.5 x |

FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} | |
---|---|---|---|---|

## Net Income | $38 m | $34.7 m | $35.5 m | $32.2 m |

## Accounts Receivable | ||||

## Inventories | ||||

## Accounts Payable | ||||

## Cash From Operating Activities | $44.4 m | $38.3 m | $42.8 m | $37.2 m |

## Purchases of PP&E | ($3.2 m) | ($5.3 m) | ($4.6 m) | ($4 m) |

## Cash From Investing Activities | ($3.3 m) | ($7 m) | ($3.6 m) | ($66.7 m) |

## Dividends Paid | ($31.4 m) | ($32.8 m) | ($33.4 m) | ($33.6 m) |

## Interest Paid | $879 k | |||

## Income Taxes Paid | $20.1 m | $20 m | $20.2 m | $17.9 m |